CMPS COMPASS Pathways ADS

COMPASS Pathways plc to participate in HC Wainwright and ICR investor conferences

COMPASS Pathways plc to participate in HC Wainwright and ICR investor conferences

London, UK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in two investor conferences during the week of 11 January 2021.  

George Goldsmith, Chairman, CEO and Co‑founder, and Lars Wilde, President, Chief Business Officer, and Co‑founder, will be participating in a fireside chat available on demand from 11 to 14 January in conjunction with the HC Wainwright BioConnect 2021 Conference.

George Goldsmith and Lars Wilde will also present a business update and hold a fireside chat at 12:15 pm ET on 14 January at the Westwicke Healthcare Day at the ICR Conference 2021.

Audio webcasts of the fireside chats will be available on the "Events" page of the Investors section of the COMPASS website at /news-events/events. A replay of events will be available for 30 days following the event.  

-Ends-

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 21 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing.

Contacts:

Media: Tracy Cheung, ,

Investors: Stephen Schultz, ,



 

 



 



 

 

 



EN
06/01/2021

Underlying

CMPSCOMPASS Pathways ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on COMPASS Pathways ADS

 PRESS RELEASE
Free
CMPS COMPASS Pathway...

Compass Pathways announces second quarter 2024 financial results and b...

Compass Pathways announces second quarter 2024 financial results and business highlights Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million Conference call August 1 at 8:00 am ET (1:00 pm UK) LONDON and NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerati...

August 1, 2024 1 EN
 PRESS RELEASE
Free
CMPS COMPASS Pathway...

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Compass Pathways appoints Lori Englebert as Chief Commercial Officer New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Engl...

June 26, 2024 1 EN
 PRESS RELEASE
Free
CMPS COMPASS Pathway...

Compass Pathways Announces First Quarter 2024 Financial Results and Bu...

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD)Michael Gold to join Compass as Head of R&DCompass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care Cash position of $262.9 million at March 31, 2024 Conference call May 8 at 8:00 a...

May 8, 2024 1 EN
 PRESS RELEASE
Free
CMPS COMPASS Pathway...

Compass Pathways announces durable improvement in symptoms through 12 ...

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 point reduction at week 12), with change from baseline in mean SDS total score (14.4 point reduction at week 12)81.8% response (reduction of ≥ 15 points in CAPS-5 score), 63.6% remission (total CAPS-5 ≤ 20) rates at week 4 with 77.3% re...

May 8, 2024 1 EN
 PRESS RELEASE
Free
CMPS COMPASS Pathway...

Compass Pathways establishes research collaboration with Mindful Healt...

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Mindful Health Solutions (MHS), one of the US’s leading providers of innovative behavioral health care, today announced that they have entered into a research collaboration agreement t...

May 2, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch